SWSusan Waserman

Susan Waserman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susan Waserman has a total of 543 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    The International/Canadian hereditary angioedema guideline

    by Stephen Betschel, Karen Binkley, Rozita Borici-Mazi, Hugo Chapdelaine, Jacques Hébert, Amin Kanani, Paul K. Keith, Gina Lacuesta, Susan Waserman, William Yang, et al.

    This update to the 2019 Canadian Hereditary Angioedema (HAE) Guideline broadens its focus to include the management of patients with HAE worldwide, building on its established international framework. It has been developed through a collaboration of Canadian and international HAE experts and patient groups, coordinated by the Canadian Hereditary Angioedema Network. The objective is to provide evidence-based recommendations, using the Grading of Recommendations Assessment, Development and Evaluation system, for the management of patients with HAE. These include recommendations for the treatment of attacks, short-term prophylaxis, and long-term prophylaxis, as well as recommendations for self-administration, individualized therapy, health-related quality of life, and comprehensive care. New to the 2024 edition are specific recommendations for the treatment of angioedema attacks in individuals with HAE who are breastfeeding/lactating, as well as a dedicated section on shared decision-making. HAE results in spontaneous and often unpredictable attacks of painful swelling, typically affecting the extremities, bowel mucosa, genitals, face, and upper airway. These attacks are associated with significant functional impairment, reduced health-related quality of life, and in the case of laryngeal attacks, a high risk of mortality. Managing HAE is complex, and patient care in Canada, similar to many other countries, remains inconsistent and suboptimal. Care delivery lags behind nations that have implemented more structured management models for HAE, and offer broader access to a wider range of approved therapies. This guideline is intended to be used to optimize HAE management, highlight the importance of individualized care, and provide guidance to healthcare providers, policymakers, patients, and advocates. Primary target users include healthcare providers who are managing patients with HAE, as well as emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, otolaryngologists, pediatricians, hematologists, dermatologists, and gynecologists who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.


  • Pathogenic IgE-fated memory B cell responses retain functional plasticity

    by Kelly Bruton, Allyssa Phelps, Atai Ariaz, Allison Fang, Tina D. Walker, Jianping Wen, Sharon S. Khavkine-Binstock, Danielle Della Libera, Olivia Mann-Delany, Niels Peter H. Knudsen, et al.

    Long-lived immunoglobulin E (IgE) responses against innocuous environmental and dietary antigens (Ags) are maintained by an IgG1-dominant memory B cell (MBC) compartment primed for interleukin-4 (IL-4) responsiveness. The plasticity of the MBC compartment destined for IgE class switch recombination remains poorly understood. In this work, we report critical IL-4 and IL-13 dependency for the pathogenic IgE fate of type 2–polarized MBCs in allergy. Initiation of a recall response in the absence of IL-4 and IL-13 signaling diminished the type 2 MBC phenotype in mice and humans. This permitted the emergence of long-lived Ag-specific IgG2c + MBCs in mice. The divergence to a type 1–like response was dependent on interferon-γ signaling and arose from both unswitched and class-switched Ag-specific B cells in vivo. This reprogrammed fate was sustained even beyond therapeutic intervention, revealing fundamental insights into the plasticity of the allergen-specific recall response.


  • Open Access

    Health-related quality of life in hereditary angioedema patients treated with subcutaneous C1 inhibitor (C1-INH) therapy in Canada

    by Susan Waserman, Gina Lacuesta, Amin S. Kanani, Gord L. Sussman, Harold Kim, Hugo Chapdelaine, Hadi A. Goubran Messiha, Chrystyna Kalicinsky, Adil Adatia, Belinda Yap, et al.

    Background: Hereditary angioedema (HAE) therapies have demonstrated improvements in clinical symptoms and health-related quality of life (HR-QoL) in patients with HAE. Specific causes for improvement in HR-QoL have not been sufficiently explored in Canada. Objective: To understand patient perspectives on the burden of HAE and their experiences taking subcutaneous plasma-derived C1 inhibitor concentrate (SC-pdC1INH), and to investigate changes in HR-QoL domains which include physical, mental, emotional, functional, social, and medical well-being. Methods: A qualitative research design was employed using telephone interviews from May to July 2023 and a quantitative self-administered Angioedema QoL questionnaire (AE-QoL), which has a recall period of 4 weeks. A conceptual map was generated from the interviews that illustrated HR-QoL domains most important to patients. Results: This study included 20 patients (50% female; mean age of 51 years; 85% HAE Type 1/2). Patients reported more controlled HAE since starting SC-pdC1INH, with fewer attacks (85%) and even no/nearly no attacks (60%) in the past year. Patients reported emotional benefits (reduced stress/anxiety regarding potential attacks [75%], and increased confidence in managing HAE [95%]). Positive impacts also included increased productivity/less missed days from work/school (40%) and improved physical ability/well-being (50%). The total mean AE-QoL Score was 34 (range 0–87; SD 24.9), indicating a small effect of HAE on HR-QoL in the 4-week pre-interview period. Conclusion: Overall, patients on long-term prophylaxis with SC-pdC1INH reported improvements in many HR-QoL domains, but most significantly relief of stress and anxiety associated with HAE, and improvement in social and physical well-being.

  • JoVE Video Dataset

    by Saven Denha, Vitoria M. Olyntho, Jake Colautti, Dima Traboulsi, Dan Stevens, Susan Waserman, Doron D. Sommer, Manel Jordana, Joshua F.E. Koenig

    Highly multiplexed imaging enables the study of functionally diverse cells and their niches within their native tissue environments. Iterative Bleaching Extends Multiplexity (IBEX) is a cyclic immunolabeling and fluorophore inactivation technique that allows for multiple markers to be visualized on the same tissue section. Captured images can be subsequently analyzed to acquire single-cell data to define cell clusters, their localizations, and neighboring cell types. Interpreting these data relies on the ability to distinguish true marker expressions from sources of background inherent to fluorescence microscopy. Spectral IBEX, an adaptation of the IBEX protocol, integrates spectral confocal detection with computational unmixing and incorporates heparin blocking to reduce charge-based off-target binding. This combination improves the signal-to-background ratio, suppresses tissue autofluorescence, and minimizes bleed-through while also reducing acquisition time compared to conventional multi-track confocal imaging. Application to human nasal polyp tissue, a model characterized by high eosinophil content and strong autofluorescence, demonstrated reliable imaging of 26 markers across structural, immune, and cell state compartments over six imaging rounds. The resulting workflow generates high-dimensional, spatially resolved proteomic information that captures complex tissue architecture and cellular niches. Together, this optimized approach provides a robust and broadly applicable strategy for multiplexed imaging, particularly suited to tissues where autofluorescence and non-specific staining limit conventional approaches.

  • High-plex Imaging using Spectral Confocal Microscopy to Minimize Non-specific Tissue Fluorescence

    by Saven Denha, Vitoria M. Olyntho, Jake Colautti, Dima Traboulsi, Dan Stevens, Susan Waserman, Doron D. Sommer, Manel Jordana, Joshua F.E. Koenig

    Highly multiplexed imaging enables the study of functionally diverse cells and their niches within their native tissue environments. Iterative Bleaching Extends Multiplexity (IBEX) is a cyclic immunolabeling and fluorophore inactivation technique that allows for multiple markers to be visualized on the same tissue section. Captured images can be subsequently analyzed to acquire single-cell data to define cell clusters, their localizations, and neighboring cell types. Interpreting these data relies on the ability to distinguish true marker expressions from sources of background inherent to fluorescence microscopy. Spectral IBEX, an adaptation of the IBEX protocol, integrates spectral confocal detection with computational unmixing and incorporates heparin blocking to reduce charge-based off-target binding. This combination improves the signal-to-background ratio, suppresses tissue autofluorescence, and minimizes bleed-through while also reducing acquisition time compared to conventional multi-track confocal imaging. Application to human nasal polyp tissue, a model characterized by high eosinophil content and strong autofluorescence, demonstrated reliable imaging of 26 markers across structural, immune, and cell state compartments over six imaging rounds. The resulting workflow generates high-dimensional, spatially resolved proteomic information that captures complex tissue architecture and cellular niches. Together, this optimized approach provides a robust and broadly applicable strategy for multiplexed imaging, particularly suited to tissues where autofluorescence and non-specific staining limit conventional approaches.


  • Open Access

    Updates in Epinephrine Guidelines

    by Susan Waserman, Heather Cruickshank

    Epinephrine is the first line treatment for anaphylaxis, which is a serious allergic reaction that can rapidly progress and may cause death. As a nonselective adrenergic agonist, epinephrine rapidly works to increase vasoconstriction and peripheral vascular resistance, increase cardiac output, reverse bronchoconstriction and mucosal edema, and inhibit the release of mediators of inflammation from mast cells and basophils. The anaphylaxis guidelines developed by the Joint Task Force on Practice Parameters (JTFPP) in 2020, the World Allergy Organization (WAO) in 2020, and the European Academy of Allergy and Clinical Immunology (EAACI) in 2021 advise clinicians to prescribe self-injectable epinephrine to individuals at risk of anaphylaxis and educate them on when and how to administer it. In 2023, the JTFPP updated its anaphylaxis practice parameter to address seven key topic areas, including multiple questions and recommendations related to epinephrine prescription and use. The practice parameter authors graded each recommendation as conditional or strong, based in part on the certainty of the supporting evidence. We provide an overview of key recommendations and discuss their applications in the Canadian context. It is important to note that in Canada, EpiPen® autoinjectors are currently the sole epinephrine delivery devices available with premeasured doses of epinephrine for the emergency treatment of allergic reactions. These autoinjectors should be administered intramuscularly into the anterolateral thigh. Additional epinephrine devices may become available in the future, including the first epinephrine nasal spray (neffy®). There is a wider variety of epinephrine devices available in the United States, including multiple brands of epinephrine autoinjectors (Adrenaclick®, Auvi-Q®, EpiPen®/EpiPen® Jr., and generic versions). Additionally, there is one brand of epinephrine prefilled syringe (Symjepi™) and one brand of nasal spray (neffy®). Although the anaphylaxis practice parameter update was published before the U.S. Food and Drug Administration had approved neffy®, we believe its recommendations for epinephrine prescription and use may be appropriately extended to include epinephrine nasal spray where it is available.

  • Patient-Reported Outcomes on Food Immunotherapy Differ Between Countries and Foods: Results From COFAITH

    by Pablo Rodríguez del Río, Carmen Riggioni, Antoine Deschildre, Matthew Greenhawt, Sabine Schnadt, Stefania Arasi, Anna Nowak-Wegrzyn, Richard L. Wasserman, Philippe Begin, Susan Waserman, et al.


  • Open Access

    A Survey of Allergic Consumers and Allergists on Precautionary Allergen Labelling: Where Do We Go from Here?

    by François Graham, Susan Waserman, Jennifer Gerdts, Beatrice Povolo, Yvette Bonvalot, Sébastien La Vieille

    Background: Despite the widespread use of precautionary allergen labelling (PAL) by manufacturers, PAL is not always used consistently and can be a source of misinterpretation by consumers and allergists. Although its use is not specifically regulated in Canada, some voluntary guidelines exist. The aims of this study were to investigate allergic consumers’ and clinicians’ understanding of PAL, to describe consumers’ attitudes towards products with PAL, and to examine recommendations given by clinicians to their patients about these products. We also compared two groups of consumers enrolled in this study, since the majority of them (72%) were registered in the Food Allergy Canada database and the others (28%) came from representative consumers of the general population. Methods: An online survey was sent from 2 to 28 December 2021 to allergic consumers registered with Food Allergy Canada’s database and to a group of allergic consumers extracted from a panel representative of the general population and not registered with Food Allergy Canada (third-party panel). All consumer participants had a food allergy or were a parent/caregiver of a child with food allergy and had to be diagnosed by a medical professional. Considering that consumers registered via the Food Allergy Canada database could be more informed about labelling than the third-party consumer panel, we conducted a multivariate analysis (logistic regression) on the key variables related to PAL allowing to compare these two groups of participants. In addition, a separate online survey was sent to allergist members of the Canadian Society of Allergy and Clinical Immunology and provincial associations to investigate their understanding of PAL from 12 November 2021 to 16 January 2022. Results: A total of 1080 consumers and 63 allergists (29% of allergists in Canada) responded to the surveys. Fifty percent of consumers were adults with food allergy, and 50% were a parent/caregiver of a child with food allergy. Food allergy was diagnosed most commonly by an allergist in 76% of the cases. Fifty-four percent of consumers purchased products with a PAL statement at least occasionally, and more than half of consumers (53%) considered PAL a very useful tool. Most surveyed individuals (59%) had not heard of the term “individual allergen threshold” or had heard the term but did not know what it meant. The same allergic consumers were reluctant to buy food products with even a small amount of their allergen (i.e., a dose that would not trigger an allergic reaction in the vast majority of them). Half of allergists reported PAL was not useful in its current form, and 83% supported the consumption of foods with PAL to their patients in some circumstances. Conclusion: While most consumers are somewhat confident in the accuracy of ingredient information on pre-packaged foods, interpretation of PAL remains confusing by many allergic consumers. If changes are to be made based on allergen thresholds, a multi-stakeholder approach will be required with greater consumer and allergist education on risk assessment concepts to facilitate the implementation of allergen population thresholds into the application of PAL.


  • Open Access

    Allergic Reactivity and Memory Occur Independently of Sequential Switching Through IgG1

    by Joshua F. E. Koenig, Adam K. Wade‐Vallance, Rodrigo Jiménez‐Saiz, Kelly Bruton, Siyon Gadkar, Emily Grydziuszko, Tina D. Walker, Melissa E. Gordon, Amy E. Gillgrass, Justin J. Taylor, et al.

    Allergic reactions to foods are primarily driven by allergen‐binding immunoglobulin (Ig)E antibodies. IgE‐expressing cells can be generated through direct switching from IgM to IgE or a sequential class switching pathway where activated B cells first switch to an intermediary isotype, most frequently IgG1, and then to IgE. It has been proposed that sequential class switch recombination is involved in augmenting the severity of allergic reactions, generating high affinity IgE, differentiation of IgE plasma cells, and in holding the memory of IgE responses. We directly tested these possibilities by comparing the allergic immunity of wild‐type and IgG1‐deficient (hMT) mice. We found that sequential switching through IgG1 was not required to maintain the binding capacity of IgE nor for its ability to promote degranulation and elicit anaphylaxis against bona fide food allergens. Furthermore, the absence of sequential switching modestly impacted IgE affinity and clinical reactivity against hapten antigens, suggesting that the nature of the antigen impacts the requirement for sequential switching. At a cellular level, the capacity to undergo sequential switching through IgG1 provided no competitive advantage for subsequent IgE expression among germinal center B cells or plasma cells. Furthermore, the recall of allergic immunity at memory timepoints was preserved in the absence of sequential switching through IgG1, a finding that corresponded with intact type 2 memory B cell polarization. Together, these data demonstrate that sequential switching through IgG1 is redundant in sensitization, anaphylaxis, and the persistence of allergy, ultimately revealing that IgE derived from any switching source should be targeted by novel therapeutics seeking to ameliorate allergic diseases.


  • Open Access

    Abstract Presentation Highlights from the 2024 EAACI Annual Meeting

    by Susan Waserman, Jason Ohayon, Paul Keith

    Many oral abstracts, posters and case reports were presented at The European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting which was held in June 2024 in Valencia, Spain. We have selected the following 13 articles due to their relevance to Canadian allergy and immunology clinical practice and research.